Skip to main content
v2026.11,986 entries · CC-BY 4.0
LAC HealthSponsored

Shop powerbreathe supplies

  • FDA registered
  • ISO 13485
  • BBB Accredited A+

Shop at LAC Health

POWERbreathe: What It Is and What the Evidence Shows

POWERbreathe explained: inspiratory vs expiratory trainers, model families, maker precautions, and what 23 systematic reviews say about IMT.

Written and maintained by CASRAI Editorial Board

Published

On this page

General information only, not medical advice. This page does not tell any person whether or how to use a breathing trainer; that decision belongs to a clinician who knows the person’s history.

Short answer

POWERbreathe is a brand of handheld breathing trainers made by POWERbreathe International. Most of its range is built for inspiratory muscle training (IMT), meaning breathing in against a resistance to exercise the muscles of inhalation; one line, the EX1, is for expiratory muscle training (EMT). A 2025 overview of 23 systematic reviews found the most consistent effect of IMT in chronic respiratory disease was higher maximal inspiratory pressure, but the certainty of the evidence was mostly low to very low.

Definition and scope

The Torres-Castro et al. overview (Frontiers in Sports and Active Living, 2025) describes IMT as a rehabilitative intervention that strengthens the inspiratory muscles using “inspiratory threshold loading devices that provide a fixed resistance to inhalation.” That is the device category this page covers: a hand-held trainer the user breathes through, as distinct from diagnostic or monitoring devices such as a peak flow meter or an incentive spirometer, which measure or prompt breathing rather than load it.

The manufacturer’s own precautions page states that its devices do not diagnose, treat, cure or prevent disease. That wording matters for anyone writing product descriptions, patient information or procurement notes: the maker positions the products as training devices, not as therapies.

How it is used in practice

At maker level, the products are used for short, regular sessions of resisted breathing, with the resistance set on the device. The manufacturer publishes its own instructions and training guidance for each model, and those documents, not a third-party summary, are the reference for settings, session structure and cleaning. Where a clinical programme uses IMT, the protocol (load, frequency, duration) is set by the clinician; the systematic reviews cited below note that the devices and protocols used across trials varied widely.

The manufacturer’s precaution list includes: do not use while distracted (for example walking, running or driving); do not share the device; stop if it causes pain; avoid use during a cold, sinusitis or other respiratory infection; adult supervision for users under 16, and not for children under 7 because of small parts.

Model families

Groupings below follow the manufacturer’s website (powerbreathe.com, read 2026-11-07). The site’s read pages do not describe the load mechanism, so none is stated here.

Family Stated purpose Category
Plus Inspiratory muscle training IMT
K-Series (for example K5) Inspiratory muscle training; the precautions page adds a note for users with a pacemaker or magnetic implant IMT
EX1 Expiratory muscle training EMT
Smart Adaptor with ActiBreathe app Bluetooth connection for tracking sessions Accessory
Shaker Deluxe, Flow-Ball Ultra Listed by the maker for mucus clearance Airway clearance

The practical distinction for clinic and supply staff is direction: IMT devices load inhalation, EMT devices load exhalation, and the maker lists different contraindication checks for each.

Do respiratory resistance trainers work?

The best-synthesised answer is conditional. Torres-Castro et al. overviewed 23 systematic reviews (21 with meta-analysis) of IMT in chronic respiratory disease. Their findings:

  • The most consistent effect was an increase in maximal inspiratory pressure (MIP). In COPD the reported increase was 10.9 cmH2O; in pulmonary hypertension, 21.2 cmH2O.
  • Exercise tolerance, measured by six-minute walk distance, rose by 35.7 m in COPD and 39.0 m in pulmonary hypertension.
  • Breathlessness (dyspnoea) was reduced in COPD, asthma and pulmonary hypertension.
  • Certainty ranged from very low to moderate on GRADE, and no outcome reached high. Moderate certainty applied only to a few outcomes, such as COPD exercise tolerance, asthma MIP and obstructive sleep apnoea MIP.
  • Methodological quality of the reviews was weak: only two were rated high on AMSTAR 2, and most were low or critically low.

The authors list the variety of devices and training protocols as a limitation and call for more high-quality studies. These results cover people with chronic respiratory disease; they do not establish effects for healthy users or athletes, and they do not rank one brand against another.

Precautions and who should check with a clinician

The manufacturer’s precautions and contraindications page groups conditions into categories. For IMT it lists some conditions for case-by-case clinical judgment (for example a history of spontaneous pneumothorax, pulmonary hypertension or large bullae, marked osteoporosis with rib fractures, and low oxygen saturation), some for which it does not recommend use until medical clearance (such as recent abdominal, oesophageal, chest, cardiac or head and neck surgery, lung resection or transplant), and some it lists as contraindications (such as a ruptured eardrum, asthma with very low symptom perception or frequent severe exacerbations, and signs of worsening heart failure). For EMT it adds further checks, including a Valsalva contraindication review, raised intraocular pressure, pregnancy, untreated reflux and untreated hypertension. Staff who stock, issue or describe these devices should point people to the maker’s full page and to their own clinician rather than paraphrase it.

Regulatory classification is a separate question from training use. For how the FDA classifies devices and what labeling must say, see the CASRAI guides on Class II medical devices, FDA labeling requirements and over-the-counter medical devices.

Common misunderstandings

  • “It is a treatment.” The maker states that its devices do not diagnose, treat, cure or prevent disease. Any clinical benefit is claimed in the research literature for specific trial populations and protocols, not by the product label.
  • “The trials prove it works.” The overview found effects on MIP most consistently, but the certainty was mostly low to very low, and the reviews themselves were mostly of low quality.
  • “It is the same as a spirometer.” Spirometers and peak flow meters measure or prompt breathing; trainers apply a load.
  • “Inspiratory and expiratory trainers are interchangeable.” They exercise different phases of breathing and carry different precaution lists.
  • “Marketing slogans are evidence.” Phrases such as the maker’s “World’s No.1 Breathing Trainer” or “NHS approved” are the company’s own statements and are not findings of the studies above.

FAQ

Do respiratory resistance trainers work?

In people with chronic respiratory disease, reviews most consistently report higher maximal inspiratory pressure, with smaller and less certain gains in walking distance and breathlessness. Certainty of evidence is mostly low to very low (Torres-Castro et al., 2025).

How to use a power breather?

Follow the instructions supplied with the specific model and the programme set by a clinician; this page does not give step-by-step instructions. The manufacturer’s general cautions include not using it while distracted, not sharing it, and stopping if it causes pain.

What are some examples of breathing exercise equipment?

Inspiratory muscle trainers (such as the POWERbreathe Plus and K-Series), expiratory muscle trainers (such as the EX1), airway-clearance devices (such as the maker’s Shaker Deluxe and Flow-Ball Ultra), and measuring or prompting devices such as incentive spirometers and peak flow meters.

What are the benefits of using POWERbreathe?

The manufacturer markets benefits on its own site. In independent research, the best-summarised outcome for IMT in chronic respiratory disease is increased MIP, with some evidence of better exercise tolerance and less breathlessness, at mostly low certainty.

Sources

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · free to try

Ask about POWERbreathe: What It Is and What the Evidence Shows

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →